Literature DB >> 33445752

Activation of an Effective Immune Response after Yellow Fever Vaccination Is Associated with the Genetic Background and Early Response of IFN-γ and CLEC5A.

Tamiris Azamor1,2, Andréa Marques Vieira da Silva1, Juliana Gil Melgaço1, Ana Paula Dos Santos1, Caroline Xavier-Carvalho2, Lucia Elena Alvarado-Arnez3, Leonardo Ribeiro Batista-Silva4, Denise Cristina de Souza Matos1, Camilla Bayma1, Sotiris Missailidis1, Ana Paula Dinis Ano Bom1, Milton Ozorio Moraes2, Patrícia Cristina da Costa Neves1.   

Abstract

The yellow fever vaccine (YF17DD) is highly effective with a single injection conferring protection for at least 10 years. The YF17DD induces polyvalent responses, with a TH1/TH2 CD4+ profile, robust T CD8+ responses, and synthesis of interferon-gamma (IFN-γ), culminating in high titers of neutralizing antibodies. Furthermore, C-type lectin domain containing 5A (CLEC5A) has been implicated in innate outcomes in other flaviviral infections. Here, we conducted a follow-up study in volunteers immunized with YF17DD, investigating the humoral response, cellular phenotypes, gene expression, and single nucleotide polymorphisms (SNPs) of IFNG and CLEC5A, to clarify the role of these factors in early response after vaccination. Activation of CLEC5A+ monocytes occurred five days after vaccination (DAV). Following, seven DAV data showed activation of CD4+ and CD8+T cells together with early positive correlations between type II IFN and genes of innate antiviral response (STAT1, STAT2, IRF7, IRF9, OAS1, and RNASEL) as well as antibody levels. Furthermore, individuals with genotypes rs2430561 AT/AA, rs2069718 AG/AA (IFNG), and rs13237944 AC/AA (CLEC5A), exhibited higher expression of IFNG and CLEC5A, respectively. Together, we demonstrated that early IFN-γ and CLEC5A responses, associated with rs2430561, rs2069718, and rs13237944 genotypes, may be key mechanisms in the long-lasting immunity elicited by YF17DD.

Entities:  

Keywords:  CLEC5A; interferon gamma; yellow fever vaccine

Year:  2021        PMID: 33445752      PMCID: PMC7828179          DOI: 10.3390/v13010096

Source DB:  PubMed          Journal:  Viruses        ISSN: 1999-4915            Impact factor:   5.048


  51 in total

Review 1.  Yellow fever vaccine.

Authors:  Thomas P Monath
Journal:  Expert Rev Vaccines       Date:  2005-08       Impact factor: 5.217

2.  Detection of Th1/Th2 cytokine signatures in yellow fever 17DD first-time vaccinees through ELISpot assay.

Authors:  A P Santos; D C S Matos; A L Bertho; S C F Mendonça; R Marcovistz
Journal:  Cytokine       Date:  2008-04-02       Impact factor: 3.861

3.  Single nucleotide polymorphisms in candidate genes and dengue severity in children: a case-control, functional and meta-analysis study.

Authors:  Caroline Xavier-Carvalho; Gerusa Gibson; Patrícia Brasil; Ralph X Ferreira; Reinaldo de Souza Santos; Oswaldo Gonçalves Cruz; Solange Artimos de Oliveira; Marília de Sá Carvalho; Antonio G Pacheco; Claire F Kubelka; Milton O Moraes
Journal:  Infect Genet Evol       Date:  2013-09-07       Impact factor: 3.342

4.  Persistence of neutralizing antibody 30-35 years after immunization with 17D yellow fever vaccine.

Authors:  J D Poland; C H Calisher; T P Monath; W G Downs; K Murphy
Journal:  Bull World Health Organ       Date:  1981       Impact factor: 9.408

5.  Association between the IFNG +874A/T gene polymorphism and leprosy resistance: a meta-analysis.

Authors:  G A V Silva; F G Naveca; R Ramasawmy; A L Boechat
Journal:  Cytokine       Date:  2014-01-02       Impact factor: 3.861

6.  Zika Virus Infects Newborn Monocytes Without Triggering a Substantial Cytokine Response.

Authors:  Fabio Seiti Yamada Yoshikawa; Anna Julia Pietrobon; Anna Cláudia Calvielli Castelo Branco; Nátalli Zanete Pereira; Luanda Mara da Silva Oliveira; Clarisse Martins Machado; Alberto José da Silva Duarte; Maria Notomi Sato
Journal:  J Infect Dis       Date:  2019-06-05       Impact factor: 5.226

7.  Genetic variants in IFNG and IFNGR1 and tuberculosis susceptibility.

Authors:  Shouquan Wu; Yu Wang; Miaomiao Zhang; Minggui Wang; Jian-Qing He
Journal:  Cytokine       Date:  2019-07-13       Impact factor: 3.861

Review 8.  IL-6 in inflammation, immunity, and disease.

Authors:  Toshio Tanaka; Masashi Narazaki; Tadamitsu Kishimoto
Journal:  Cold Spring Harb Perspect Biol       Date:  2014-09-04       Impact factor: 10.005

9.  Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity.

Authors:  Troy Querec; Soumaya Bennouna; Sefik Alkan; Yasmina Laouar; Keith Gorden; Richard Flavell; Shizuo Akira; Rafi Ahmed; Bali Pulendran
Journal:  J Exp Med       Date:  2006-02-06       Impact factor: 14.307

10.  Early IFN-gamma production after YF 17D vaccine virus immunization in mice and its association with adaptive immune responses.

Authors:  Patrícia C C Neves; Juliana R Santos; Luciana N Tubarão; Myrna C Bonaldo; Ricardo Galler
Journal:  PLoS One       Date:  2013-12-06       Impact factor: 3.240

View more
  2 in total

Review 1.  Vaccines and Senior Travellers.

Authors:  Fiona Ecarnot; Stefania Maggi; Jean-Pierre Michel; Nicola Veronese; Andrea Rossanese
Journal:  Front Aging       Date:  2021-07-09

2.  Protective Immunity of COVID-19 Vaccination with ChAdOx1 nCoV-19 Following Previous SARS-CoV-2 Infection: A Humoral and Cellular Investigation.

Authors:  Tamiris Azamor; Ingrid Siciliano Horbach; Danielle Brito E Cunha; Juliana Gil Melgaço; Andréa Marques Vieira da Silva; Luciana Neves Tubarão; Adriana de Souza Azevedo; Renata Tourinho Santos; Nathalia Dos Santos Alves; Thiago Lazari Machado; Jane Silva; Alessandro Fonseca de Souza; Camilla Bayma; Vanessa Pimenta Rocha; Ana Beatriz Teixeira Frederico; Brenda de Moura Dias; Bruno Pimenta Setatino; Caio Bidueira Denani; Samir Pereira da Costa Campos; Waleska Dias Schwarcz; Michel Vergne Sucupira; Edinea Pastro Mendes; Edimilson Domingos da Silva; Sheila Maria Barbosa de Lima; Ana Paula Dinis Ano Bom; Sotiris Missailidis
Journal:  Viruses       Date:  2022-08-30       Impact factor: 5.818

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.